Likewise, mutations in the APOB gene weaken the binding of LDL to LDL receptors, and gain-of-function mutations in the PCSK9 gene account for 5–15% of cases with FH (El Khoury et al., 2017; Sharifi et al., 2017). This evidence concerns the gene PCSK9 and familial hyperaldosteronism.